Difference between revisions of "Small bowel adenocarcinoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"" to "<!-- {| class="wikitable" style="margin:auto; color:white; background-color:#1B4F26"") |
m (→Guidelines) |
||
Line 11: | Line 11: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
+ | ==French Intergroup== | ||
+ | *'''2017:''' Locher et al. [https://doi.org/10.1016/j.dld.2017.09.123 Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)] [https://pubmed.ncbi.nlm.nih.gov/29174568/ PubMed] | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
*[https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf NCCN Guidelines - Small Bowel Adenocarcinoma] | *[https://www.nccn.org/professionals/physician_gls/pdf/small_bowel.pdf NCCN Guidelines - Small Bowel Adenocarcinoma] |
Revision as of 01:05, 17 October 2023
Section editor | |
---|---|
Travis Zack, MD, PhD University of California San Francisco San Francisco, CA, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
French Intergroup
- 2017: Locher et al. Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO) PubMed
NCCN
Subsequent lines of therapy
Pembrolizumab monotherapy
Regimen
FDA-recommended dose |
Study | Dates of enrollment | Evidence |
---|---|---|
Marabelle et al. 2019 (KEYNOTE-158) | 2016-2018 | Phase 2 (RT) |
Note: 7.4% of patients enrolled in KEYNOTE-158 cohort K had small intestine cancer.
Biomarker eligibility criteria
- MSI-H or dMMR
Immunotherapy
- Pembrolizumab (Keytruda) 200 mg IV over 30 minutes once on day 1
21-day cycle for up to 35 cycles (2 years)
References
- KEYNOTE-158: Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020 Jan 1;38(1):1-10. Epub 2019 Nov 4. link to original article link to PMC article PubMed NCT02628067
- Update: Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, Miller WH, Oh DY, Gottfried M, Xu L, Jin F, Norwood K, Marabelle A. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022 Sep;33(9):929-938. Epub 2022 Jun 6. link to original article PubMed